Handelsbanken Fonder AB Increases Stock Position in Insmed Incorporated (NASDAQ:INSM)

Handelsbanken Fonder AB lifted its holdings in Insmed Incorporated (NASDAQ:INSM) by 3.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,281 shares of the biopharmaceutical company’s stock after buying an additional 1,700 shares during the quarter. Handelsbanken Fonder AB’s holdings in Insmed were worth $3,126,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. V Square Quantitative Management LLC grew its holdings in Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 248 shares during the period. Spire Wealth Management purchased a new stake in shares of Insmed in the 4th quarter worth approximately $47,000. Venturi Wealth Management LLC bought a new position in Insmed during the 4th quarter valued at approximately $86,000. Blue Trust Inc. raised its stake in Insmed by 2,348.8% during the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 1,879 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in Insmed in the third quarter worth $133,000.

Insmed Stock Performance

INSM opened at $80.03 on Tuesday. The company’s 50 day moving average is $74.43 and its 200 day moving average is $73.67. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market cap of $14.32 billion, a price-to-earnings ratio of -14.32 and a beta of 1.11. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The business had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. On average, equities research analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.

Insider Activity at Insmed

In other Insmed news, CFO Sara Bonstein sold 3,470 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $65.70, for a total transaction of $227,979.00. Following the sale, the chief financial officer now owns 114,736 shares in the company, valued at approximately $7,538,155.20. This trade represents a 2.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the completion of the transaction, the chief executive officer now owns 334,186 shares of the company’s stock, valued at approximately $27,079,091.58. The trade was a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 532,207 shares of company stock worth $41,400,465. Corporate insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on INSM. HC Wainwright restated a “buy” rating and set a $90.00 price target on shares of Insmed in a report on Friday. Truist Financial raised their price objective on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research note on Friday. Morgan Stanley upped their target price on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Stifel Nicolaus cut their target price on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a research note on Friday. Finally, JPMorgan Chase & Co. boosted their price target on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $91.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.